What is the LENZ Therapeutics, Inc. stock price forecast?

LENZ Therapeutics, Inc. is currently trading at $6.52. View real-time AI analysis on Alpha Lenz.

What is LENZ Therapeutics, Inc. insider trading activity?

View the latest insider trading data for LENZ Therapeutics, Inc. on Alpha Lenz.

What is LENZ Therapeutics, Inc.'s P/E ratio?

LENZ Therapeutics, Inc.'s P/E ratio is -2.3.

LENZ Therapeutics, Inc.

NASDAQ · LENZ

$6.52-0.11(-1.66%)Pre-market

Ask about LENZ Therapeutics, Inc.'s future dividend policy...

Alpha Chat Insight

“LENZ Therapeutics, Inc. trades at a P/E of -2.3 (undervalued) with modest ROE of -33.6%.”

Ask for details →

Company Overview

Lenz Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapies to address unmet medical needs in ophthalmology. The company primarily works on advancing treatments for presbyopia and other eye-related conditions. With an emphasis on research and development, Lenz Therapeutics Inc. leverages cutting-edge medical technology to revolutionize how eye disorders are managed. The firm is involved in clinical trials and regulatory processes to ensure the efficacy and safety of its novel therapeutic offerings. As a significant player in the healthcare and pharmaceutical sectors, Lenz Therapeutics contributes to the broader market by potentially providing new treatment options that could enhance patient outcomes. The company's commitment to innovation in eye care represents an essential advancement in addressing vision impairments, benefiting both patients and healthcare providers.

CEOMr. Evert B. Schimmelpennink

Websitehttps://www.lenz-tx.com

SectorHealthcare

IndustryBiotechnology

Employees6

Company Statistics

FY 2025

Profile

$187.86MMarket Cap

$19.09MRevenue

0.00Shares Out

6Employees

Margins

97.81%Gross

-475.96%EBITDA

-477.46%Operating

-427.62%Pre-Tax

-430.25%Net

Valuation

-2.29P/E

0.66P/B

9.84EV/Sales

-1.80EV/EBITDA

-2.68P/FCF

Growth (CAGR)

8.37%Rev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-31.52%ROA

-33.63%ROE

-34.97%ROIC

Financial Health

$25.18MCash & Cash Equivalents

$-3.64MNet Debt

7.57%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“LENZ Therapeutics, Inc. trades at a P/E of -2.3 (undervalued) with modest ROE of -33.6%.”

Ask for details →

Frequently Asked Questions

LENZ Therapeutics, Inc. (ticker: LENZ) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 6 employees. Market cap is $188M.

The current price is $6.52 with a P/E ratio of -2.29x and P/B of 0.66x.

ROE is -33.63% and operating margin is -477.46%. Annual revenue is $19M.